Search Results - "Havlin, K"

A phase I trial of taxol given by a 6-hour intravenous infusion by Brown, T, Havlin, K, Weiss, G, Cagnola, J, Koeller, J, Kuhn, J, Rizzo, J, Craig, J, Phillips, J, Von Hoff, D

“…Taxol is a unique mitotic inhibitor that has entered phase II investigation. Phase I studies demonstrated hypersensitivity reactions that were related to the…”
Get more information

High-dose ketoconazole in advanced hormone-refractory prostate cancer: endocrinologic and clinical effects by Trump, D L, Havlin, K H, Messing, E M, Cummings, K B, Lange, P H, Jordan, V C

“…High-dose ketoconazole (400 mg orally three times a day) and physiologic replacement doses of glucocorticoids (hydrocortisone, 20 mg 8 AM, 10 mg 4 PM, and 8…”
Get more information

Phase I clinical trial of gemcitabine given as an intravenous bolus on 5 consecutive days by O'Rourke, T J, Brown, T D, Havlin, K, Kuhn, J G, Craig, J B, Burris, H A, Satterlee, W G, Tarassoff, P G, Von Hoff, D D

Get more information

Inability to escalate vinorelbine dose intensity using a daily x3 schedule with and without filgrastim in patients with metastatic breast cancer by HAVLIN, K. A, RAMIREZ, M. J, LEGLER, C. M, HARRIS, L. N, MATULONIS, U. A, HOHNEKER, J. A, HAYES, D. F, WINER, E. P

“…Vinorelbine (Navelbine) is a semi-synthetic vinca alkaloid with documented activity in breast cancer. The major dose-limiting toxicity (DLT) when given weekly…”
Get full text

Phase I clinical investigation of amonafide by Saez, R, Craig, J B, Kuhn, J G, Weiss, G R, Koeller, J, Phillips, J, Havlin, K, Harman, G, Hardy, J, Melink, T J

“…Amonafide (benzisoquinolinedione, NSC 308847) is a new synthetic imide antineoplastic agent with DNA intercalative properties that has been evaluated in a…”
Get more information

Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases by Body, J.-J., Diel, I. J., Lichinitser, M. R., Kreuser, E. D., Dornoff, W., Gorbunova, V. A., Budde, M., Bergström, B.

“…Background: This phase III study compared the efficacy of the new potent bisphosphonate, ibandronate, with placebo as intravenous (i.v.) therapy in metastatic…”
Get full text

Etoposide in gastric cancer by Macdonald, J S, Havlin, K A

“…Etoposide has modest single-agent activity (21% partial response rate) in patients with previously untreated metastatic gastric carcinoma. The use of etoposide…”
Get more information

Trastuzumab and Vinorelbine as First-Line Therapy for HER2-Overexpressing Metastatic Breast Cancer: Multicenter Phase II Trial With Clinical Outcomes, Analysis of Serum Tumor Markers as Predictive Factors, and Cardiac Surveillance Algorithm by BURSTEIN, Harold J, HARRIS, Lyndsay N, RYAN, Paula D, ELLIS, Mathew J, NUNES, Raquel A, BUNNELL, Craig A, CAMPOS, Susana M, HALLOR, Michele, GELMAN, Rebecca, WINER, Eric P, MARCOM, P. Kelly, LAMBERT-FALLS, Rosemary, HAVLIN, Kathleen, OVERMOYER, Beth, FRIEDLANDER, Robert J, GARGIULO, Janet, STRENGER, Rochelle, VOGEL, Charles L

“…Trastuzumab-based therapy improves survival for women with human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer. We conducted a…”
Get full text

Phase I clinical and pharmacokinetic trial of flavone acetic acid by Havlin, K A, Kuhn, J G, Craig, J B, Boldt, D H, Weiss, G R, Koeller, J, Harman, G, Schwartz, R, Clark, G N, Von Hoff, D D

“…Flavone acetic acid is a synthetic benzopyrone derivative with an unknown mechanism of action. Thirty-eight patients (30 men and 8 women) were treated once a…”
Get more information

Is diabetes mellitus (DM) associated with worse outcomes in pancreatic cancer (PC)? by Olowokure, O. O., Beg, M. S., Ali, S., Tandra, A., Safa, M. M., Havlin, K., Ahmad, S. A.

“…Abstract only…”
Get full text

Continuous infusion 5-fluorouracil as first-line therapy for metastatic breast cancer by Chu, L, Sutton, L M, Peterson, B L, Havlin, K A, Winer, E P

“…Previous phase II studies of continuous infusion Fluorouracil (5-FU) (CI 5-FU) in refractory metastatic breast cancer have shown modest activity with low…”
Get more information

Deoxyspergualin: phase I clinical, immunologic and pharmacokinetic study by Havlin, K A, Kuhn, J G, Koeller, J, Boldt, D H, Craig, J B, Brown, T D, Weiss, G R, Cagnola, J, Phillips, J, Harman, G

“…Deoxyspergualin (DSG) is an analog of the polyamine spergualin with preclinical evidence of activity in murine and human tumor models. This phase I study…”
Get more information

Phase I trial of sulofenur (LY186641) given orally on a daily x 21 schedule by Brown, T D, O'Rourke, T J, Kuhn, J G, Craig, J B, Havlin, K, Burris, 3rd, H A, Cagnola, J, Hamilton, J M, Grindey, G B, Satterlee, W G

“…Sulofenur (LY186641), a diarylsulfonylurea, was evaluated clinically utilizing either a daily x 21 schedule or a daily x 5 (with 2 days off) for 3 weeks…”
Get more information

Phase I and clinical pharmacology trial of 502U83 using a monthly single dose schedule by VON HOFF, D. D, KUHN, J. G, WARGIN, W, HUBBELL, J, TUTTLE, R. L, KOELLER, J. M, FREEMAN, G. L, HAVLIN, K. A, LANGEVIN, A.-M, BROWN, T. D, WEISS, G. R, TURNER, J. N, PURVIS, J, SOL LUCAS, V, BAIR, K. W

“…502U83 is an arylmethylaminopropanediol derivative exhibiting significant antineoplastic activity in a number of murine and human tumor models. In this Phase I…”
Get full text

A phase I trial of trimetrexate (NSC352122) on a daily x 5 schedule in patients with refractory adult leukemia by Rodriguez, G, Brown, T D, Balis, F M, Craig, J B, Denham, C A, Kuhn, J G, Havlin, K, Von Hoff, D D

“…Seven adult patients with refractory acute leukemia were administered trimetrexate (TMTX), a non-classical folate antagonist, in a phase I trial. TMTX was…”
Get more information

Phase I evaluation of 773U82.HCl, a member of a new class of DNA intercalators by Havlin, K A, Kuhn, J G, Craig, J B, Weiss, G R, Koeller, J, Turner, J N, Luther, J S, Clark, G, Bair, K W, Wargin, W

“…The arylmethylaminopropanediols (AMAPs) are a new class of DNA intercalators. 773U82.HCl is the second of these compounds to enter clinical trial. Significant…”
Get more information

Reduced rates of metabolism and decreased physical activity in breast cancer patients receiving adjuvant chemotherapy by Demark-Wahnefried, W, Hars, V, Conaway, MR, Havlin, K, Rimer, BK, McElveen, G, Winer, EP

“…Weight gain, a common side effect among breast cancer patients receiving adjuvant chemotherapy, may decrease quality of life and impair survival. Weight gain…”
Get full text

Aminoglutethimide: theoretical considerations and clinical results in advanced prostate cancer by Havlin, K A, Trump, D L

Get more information

Trajectory of cognitive impairment during breast cancer treatment: A prospective analysis by Wagner, L. I., Sweet, J. J., Butt, Z., Beaumont, J., Havlin, K. A., Sabatino, T., Cella, D.

“…Abstract only 8500 Background: Several studies havedocumented cognitive impairment in cancer patients; however these reports are primarily based on…”
Get full text

New anticancer agents by Brown, T D, Burris, H A, Havlin, K A, O'Rourke, T J, Rodriguez, G I, Wall, J G, Weiss, G R

Get more information